BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Mabwell's Nectin-4 Targeting ADC Secures IND Approval for Clinical Trials in Perioperative Urothelial Carcinoma and Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW...

November 15, 2024 | News

Perth’s Lixa Kicks Off Clinical Trial for NeoX-101, Aiming to Combat Chronic Lung Infections

Lixa, a Perth-based biotechnology company, has announced the launch of its first clinical trial to evaluate the safety and tolerability of NeoX-101, an inn...

November 14, 2024 | News

Nxera Pharma Secures $3.5M Milestone as Centessa Pharmaceuticals Launches Phase 2 Trial of ORX750 for Sleep Disorders

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes t...

November 14, 2024 | News

Transgene and NEC Unveil Positive 24-Month Data for TG4050 Cancer Vaccine in Adjuvant Treatment of Head and Neck Cancer at SITC 2024

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Cor...

November 14, 2024 | News

Taiwan's Caliway Biopharmaceuticals Receives EMA Orphan Drug Designation for CBL-514 in Dercum’s Disease Treatment

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment.- CBL-514 received both FDA Orphan Drug...

November 14, 2024 | News

Ascletis Completes Enrollment for Phase III Trial of ASC40 in Acne

Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 Ascletis Pharma Inc. ann...

November 13, 2024 | News

Alphamab Oncology’s JSKN033 Receives Fast-Track Approval from Shanghai Drug Authority for Innovative Cancer Therapy Clinical Trials

Alphamab Oncology (stock code: 9966.HK) announced that a clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulatio...

November 13, 2024 | News

Nordic Bioscience Secures FDA Letter of Support for CPa9-HNE Biomarker in Advancing IBD Clinical Trials

Nordic Bioscience, a leading biomarker company, announced that its CPa9-HNE biomarker assay received a Letter of Support (LoS) from the U.S. Food and Drug ...

November 12, 2024 | News

China’s Gan & Lee’s GZR18 Injection Achieves Up to 17.8% Weight Loss in Phase 2b Trial

Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean ...

November 12, 2024 | News

Harbour BioMed Files IND Application in China for Novel Antibody Therapy HBM9378/SKB378 Targeting COPD

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ant...

November 11, 2024 | News

Dizal Submits NDA to U.S. FDA for Sunvozertinib as a New Treatment Option for Advanced NSCLC with EGFR Exon 20 Insertion Mutations

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announ...

November 11, 2024 | News

Aditum Bio and Leads Biolabs Launch Oblenio Bio to Advance First-in-Class Tri-Specific Antibody for Autoimmune Diseases

Aditum Bio and Leads Biolabs announced the formation of Oblenio Bio, which is being formed in conjunction with an exclusive option and license agreeme...

November 08, 2024 | News

Ascletis' ASC47 Shows Promise in Phase I Trial with Once-Monthly Dosing and Superior Fat Reduction in Obesity Treatment

Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed...

November 08, 2024 | News

Minghui Pharmaceutical Announces Promising Phase I Results for MHB039A, a PD-1 x VEGF Bispecific Antibody, in Solid Tumor Treatment in China

Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today annou...

November 07, 2024 | News

Stay Connected